Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
5.54Last Year’s EPS
3.92Same Quarter Last Year
Strong Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -20.44%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented strong financial growth driven by key products, successful trial results, and significant investments in manufacturing. However, challenges remain with regulatory hurdles, potential tariff impacts, and market dynamics in the obesity segment. The balance of positive revenue growth and strategic investments against these challenges suggests a cautiously optimistic outlook.Company Guidance
During the Q1 2025 earnings call, Eli Lilly & Company reported a robust financial performance with a 45% increase in revenue compared to Q1 2024, driven by key products like Mounjaro, Zepbound, and Verzenio. The company's gross margin was 83.5%, with marketing expenses increasing by 26% and R&D expenses by 8%. Lilly achieved several pipeline milestones, including the approval of Omvoh in the U.S., EU, and Japan. They also announced significant U.S. manufacturing investments exceeding $50 billion since 2020. Despite the impact of acquired IPR&D charges reducing earnings per share by $1.72, the company delivered an EPS of $3.34. Looking ahead, Lilly anticipates further clinical trial readouts for orforglipron and potential regulatory submissions for obesity treatments by year-end 2025, while maintaining a focus on expanding their product pipeline and manufacturing capabilities.Strong Revenue Growth
Revenue grew 45% compared to Q1 of 2024, driven by key products like Mounjaro and Zepbound, which contributed over $4 billion in growth and accounted for $7.5 billion of the company's revenue.
Phase 3 Orforglipron Trial Success
Orforglipron achieved significant results in its Phase 3 trial for Type 2 diabetes, with hemoglobin A1c reductions of 1.3% to 1.6% and weight loss of approximately 16 pounds or 7.9% body weight at the highest dose.
Manufacturing Investment Expansion
Lilly announced over $50 billion in new U.S. manufacturing investments since 2020, including plans to build four new facilities, three of which will be active pharmaceutical ingredient facilities.
Strong Performance of Mounjaro and Zepbound
Mounjaro sales were $3.8 billion, more than double the same quarter last year, and Zepbound sales increased by $1.8 billion to $2.3 billion, making it the U.S. market leader in anti-obesity prescriptions.
Strong Financial Performance Metrics
Gross margin increased to 83.5% in Q1, and the non-GAAP performance margin was 42.6%, an increase of over 11 percentage points from Q1 2024.
LLY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LLY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2025 | $897.11 | $792.48 | -11.66% |
Feb 06, 2025 | $839.01 | $867.10 | +3.35% |
Oct 30, 2024 | $898.69 | $842.25 | -6.28% |
Aug 08, 2024 | $766.89 | $839.56 | +9.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Eli Lilly & Co (LLY) report earnings?
Eli Lilly & Co (LLY) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Eli Lilly & Co (LLY) earnings time?
Eli Lilly & Co (LLY) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LLY EPS forecast?
LLY EPS forecast for the fiscal quarter 2025 (Q2) is 5.54.
